2024-05-02 18:00 | UU:NKTR | | News Release200 | Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets |
2024-03-22 14:00 | UU:NKTR | | News Release200 | Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference |
2024-03-05 09:00 | UU:NKTR | | News Release200 | Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata |
2024-03-04 16:15 | UU:NKTR | | News Release200 | Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results |
2024-03-04 08:30 | UU:NKTR | | News Release200 | Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX |
2024-02-27 18:00 | UU:NKTR | | News Release200 | Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference |
2024-02-26 18:00 | UU:NKTR | | News Release200 | Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets |
2024-01-03 18:00 | UU:NKTR | | News Release200 | Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA |
2023-12-11 18:00 | UU:NKTR | | News Release200 | Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting |
2023-11-07 16:15 | UU:NKTR | | News Release200 | Nektar Therapeutics Reports Third Quarter 2023 Financial Results |
2023-10-31 18:00 | UU:NKTR | | News Release200 | Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets |
2023-10-13 08:30 | UU:NKTR | | News Release200 | Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress |
2023-10-02 09:00 | UU:NKTR | | News Release200 | Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy |
2023-09-27 09:00 | UU:NKTR | | News Release200 | Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer |
2023-09-13 09:00 | UU:NKTR | | News Release200 | Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis |
2023-09-06 18:00 | UU:NKTR | | News Release200 | Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th |
2023-08-08 16:15 | UU:NKTR | | News Release200 | Nektar Therapeutics Reports Second Quarter 2023 Financial Results |
2023-08-07 06:30 | UU:NKTR | | News Release200 | Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company |
2023-08-01 18:00 | UU:NKTR | | News Release200 | Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets |
2023-06-12 18:00 | UU:NKTR | | News Release200 | Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference |
2023-05-09 16:15 | UU:NKTR | | News Release200 | Nektar Therapeutics Reports First Quarter 2023 Financial Results |